Clinical characteristics of idiopathic inflammatory myopathies patients with anti-PM/Scl antibodies
Authors' conclusion
Among IIMs patients who tested positive for anti-PM/Scl antibodies, ILD emerged as the predominant clinical feature, particularly when combined with MSA. Notably, patients with isolated anti-PM/Scl antibodies exhibited a favorable prognosis following immunotherapy.
Study context
- Population
- IIM patients positive for anti-PM/Scl antibodies51 (78.5 %) females
- Participants
- 65 participants
- Exposure
- Isolated anti-PM/Scl antibodies vs anti-PM/Scl antibodies coexisting with myositis-specific antibodies (MSAs)
- Double-positiven = 34reference
- Outcome
- Clinical features
Main finding
As reported in the abstract
- Isolated anti-PM/Scl vs Double-positive
- Proportion of women 90.3 % vs 67.6 %; P = 0.026
- Isolated anti-PM/Scl vs Double-positive
- Sclerodactyly 16.1 % vs 0; P = 0.021
- Double-positive vs Isolated anti-PM/Scl
- Interstitial lung disease (ILD) 90.6 % vs 67.9 %; P = 0.028
- Double-positive vs Isolated anti-PM/Scl
- Mortality 20.6 % vs 0; P = 0.034
Observational data: associations, not effects.
Original publication
Clinical characteristics of idiopathic inflammatory myopathies patients with anti-PM/Scl antibodies. Semin Arthritis Rheum. Published 10 August 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →